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ABSTRACT
CDT2/L2DTL/RAMP is one of the substrate receptors of the Cullin Ring Ubiquitin 
Ligase 4 that targets for ubiquitin mediated degradation a number of substrates, 
such as CDT1, p21 and CHK1, involved in the regulation of cell cycle and survival. 
Here we show that CDT2 depletion was alone able to induce the apoptotic death in 
12/12 human cancer cell lines from different tissues, regardless of the mutation 
profile and CDT2 expression level. Cell death was associated to rereplication and to 
loss of CDT1 degradation. Conversely, CDT2 depletion did not affect non-transformed 
human cells, such as immortalized kidney, lung and breast cell lines, and primary 
cultures of endothelial cells and osteoblasts. The ectopic over-expression of an 
activated oncogene, such as the mutation-activated RAS or the amplified MET in 
non-transformed immortalized breast cell lines and primary human osteoblasts, 
respectively, made cells transformed in vitro, tumorigenic in vivo, and susceptible to 
CDT2 loss. The widespread effect of CDT2 depletion in different cancer cells suggests 
that CDT2 is not in a synthetic lethal interaction to a single specific pathway. CDT2 
likely is a non-oncogene to which transformed cells become addicted because of their 
enhanced cellular stress, such as replicative stress and DNA damage. 
INTRODUCTION
The evolutionarily conserved Cullin Ring Ubiquitin 
Ligase 4 (CRL4) E3 ligase family, together with its DDB1 
adaptor, regulates a diverse set of cellular processes 
including development, transcription, replication and 
DNA repair [1]. Specificity is conferred by a set of more 
than fifty substrate receptors, also referred to as DCAFs 
(DDB1 CUL4 Associated Factors). The CRL4 bound to 
the substrate receptor CDT2/L2DTL/RAMP (CRL4CDT2) 
promotes the ubiquitylation of proteins in S phase and after 
DNA damage [2-4]. In vertebrates, the CRL4CDT2 targets 
for destruction the licensing factor CDT1 [2, 3, 5, 6], the 
CDK inhibitor p21 [7, 8], the histone methyltransferase 
Set8 [9-11], the histone acetyltransferases GCN5 [12], 
the checkpoint kinase CHK1 [13] and the TOB anti-
proliferative protein [14]. The CRL4CDT2 –mediated 
destruction occurs mostly [2, 15] but not always [13] 
through its binding to the DNA-bound fraction of the 
Proliferating Cell Nuclear Antigen (PCNA). The CRL4CDT2 
has also roles outside the regulation of the cell cycle. For 
instance, SET8 destruction promotes also transcription 
and prevents premature chromatin compaction [9, 
16]. Moreover, the CRL4CDT2 targets the controller of 
heterochromatin assembly Epe1 [17], the transcription 
factor E2F in flies [18], the DNA polymerase η in worms 
[19] and the p12 subunit of the DNA polymerase δ in 
humans [20, 21], and in fission yeast the ribonucleotide 
reductase inhibitor Spd1 [22]. 
CDT2 was first discovered for its ability to 
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induce a transient increase in the proliferation rate of 
human embryonal carcinoma cells [23]. In most normal 
adult tissues CDT2 is barely detectable but in highly 
proliferating tissues, such as testis and bone marrow [23]. 
CDT2 overexpression was reported in breast [24], gastric 
[25] and ovarian carcinomas [26] and rhabdomyosarcomas 
[27] and associated with the aggressiveness of 
hepatocellular carcinomas [28]. CDT2 overexpression was 
associated with the gain of 1q where the gene is located 
[28] in Ewing sarcoma [29] and to the decrease of the miR-
30a-5p in primary colorectal carcinomas [30]. Moreover, 
in diffuse large B-cell lymphoma CDT2 increase might 
be due to mutation or deletion of the FBXO11 gene, that 
regulates CDT2 polyubiquitylation and degradation [31, 
32].
Thus, we hypothesized that CDT2 could be targeted 
for cancer therapy and silenced CDT2 in human cancer 
cell lines and human non-transformed cells. Here we show 
that CDT2 is necessary for the survival and replication of 
cancer cells, but dispensable in non-transformed cells.
RESULTS
Loss of CDT2 affects viability of cancer cells but 
not that of non-transformed cells
As we found an association between CDT2 down 
modulation and the apoptotic death of ovarian cancer cells 
[33], we investigated if down-modulation of CDT2 with 
RNA interference was alone able to commit ovarian and 
other cancer cell lines to death. 
CDT2 was suppressed in twelve cancer cell lines 
from different human tumor tissues and shown to be 
transformed and tumorigenic, and six non-transformed 
human cell lines, among which four commercially 
available cell lines (HK2, hTERT-HME-1, MCF 10A and 
MRC-5) and two primary cultures of human cells, i.e. 
Human Umbilical Vein Endothelial Cells (HUVEC) [34] 
and human osteoblasts (HOB) obtained from cultures of 
bone-derived cells [35]. These non-transformed cell lines 
and primary cultures were selected for their expression of 
CDT, that is detectable only in highly proliferating normal 
cells [23]. Details of tissues of origin and mutations of 
the commercially available cell lines are reported in the 
Supplementary Table 1, which shows that cancer cell lines 
display different mutation profiles.
CDT2 was silenced in each cell line by means of the 
transient transfection of a mixture of four small interfering 
RNAs, each targeting different sequence of the CDT2 
mRNA. The use of this siRNA pool allows avoiding too 
high concentration of each single siRNA and thus prevents 
off-target effects [36]. On the contrary, pools of siRNA 
targeting different mRNAs, such as those used in libraries, 
results in increased off-target effects [37]. As a control, 
cells were transfected with a non-targeting siRNA pool. 
Supplementary Figure 1A and 3 and Figure 3 show that 
these siRNAs were similarly efficient in down-modulating 
CDT2 in all cell lines, including the non-transformed ones. 
Depletion of CDT2 committed to death only 
cancer cell lines (Figure 1A). An increased number of 
active caspase-3-positive cells after CDT2 silencing was 
observed in cancer cell lines, but not in non-transformed 
cells (Figure 1B). These data show that CDT2 depletion 
resulted in decreased viability of cancer cell lines, due 
Figure 1: CDT2 suppression affects viability of cancer cells (grouped on the left), but not that of non-transformed 
cells (grouped on the right). Cell lines were transfected with either the CDT2 specific (siCDT2) or a control (siCTR) small interfering 
RNA pool. (A) Percentage of dead cells, measured with cytometry after cell labeling with propidium iodide: the non-transformed cell lines 
and primary cell cultures (on the right) were similarly not affected by CDT2 silencing, which induced the death of all cancer cell lines (on 
the left). (B) Percentage of apoptotic cells, measured with cytometry after cell labeling with an anti active caspase-3 antibody. In cancer 
cell lines (SK-OV-3, HeLa and A549) the number of caspase-3 positive cells increased after CDT2 silencing that did not affect the non-
transformed cell line MCF 10A. Significance was evaluated using the Student’s t-test: ** P<0.01, *P<0.05.
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to apoptosis activation. As shown in the Supplementary 
Figure 1B, no correlation was found between cell 
susceptibility to CDT2 silencing and the baseline 
level of CDT2 expression. It is noteworthy that all the 
cancer cell lines were susceptible to CDT2 silencing 
and all the non-transformed cells showed resistance, 
although in all lines a comparable protein silencing 
was achieved (Supplementary Figure 1A). To further 
confirm the specific effect of CDT2 silencing, both 
transformed and non-transformed cells were transduced 
to express shRNAs targeting a different CDT2 sequence. 
Supplementary Figure 2 shows that transformed cells, but 
not non-transformed cells were selectively killed by CDT2 
silencing.
Loss of CDT2 causes rereplication in cancer cells, 
but not in non-transformed cells
It has been shown [5, 7] that CDT2 depletion might 
cause rereplication and G2/M arrest in cells.
We evaluated the effect of CDT2 silencing on the 
cell cycle (Table 1 and Figure 2). All cancer cell lines 
showed an altered cell cycle after CDT2 suppression, 
while the cell cycle of non-transformed cells was not 
affected (Table 1 and Figure 2). In cancer cell lines, the 
number of cells in G0/G1 phase was strikingly reduced. 
Moreover, accrual of cells in G2/M and increased number 
of cells showing rereplication, i.e. cells showing DNA 
content >G2/M (>4N), were both associated to 72 hours 
long CDT2 depletion (Table 1). To better characterize the 
cell cycle blockade, we examined the status of histone H3 
Ser10-phosphorylation, that is nearly absent in interphase 
cells and occurs almost exclusively during mitosis [38]; 
histone H3 phosphorylation increases in proliferating 
cells and its decrease is indicative of lack of entry into 
mitosis. As shown in Supplementary Figure 2, after CDT2 
silencing phospho-H3 positive cells diminished in cancer 
cell lines, but not in non-transformed cell lines. These data 
show that CDT2 silencing induced cell cycle blockade, 
G2 arrest and rereplication in cancer cells, but not in non-
transformed cells.
Loss of CDT2 affects the degradation of CDT1 in 
cancer cells, but not in non-transformed cells
As all cancer cell lines underwent rereplication 
after CDT2 depletion, we inferred that the stability of the 
licencing factor CDT1 was affected. As expected, cell 
treatment with the DNA damaging agent cisplatin (CDDP) 
resulted in CDT1 degradation in both cancer and non-
transformed cells transfected with control siRNAs (Figure 
3A-B). Conversely, CDT2 silencing abrogated the CDDP 
induced degradation of CDT1 in cancer cells, while it did 
not affect CDT1 degradation in non-transformed cells 
(Figure 3A-B). In agreement, it has been shown already 
that increased level of CDT1 results in rereplication and 
cell apoptotic death [39] 
We assessed also the possible role of either p21 or 
CHK1, that are also CRL4CDT2 substrates. As shown in 
Figure 3C, p21 degradation was impaired after CDT2 
depletion, but only in p53 proficient cancer cell lines (such 
as TOV-21G) and not in p53 defective cancer cell lines 
Table 1: Cell cycles of cancer and non-transformed (non tumorigenic) cell lines after CDT2 silencing. The percentage 
of cells in each phase of the cell cycle is shown. Cell cycle analysis was carried out by labelling cells with propidium iodide 
(PI) after 72 hour long CDT2 silencing and evaluating the PI content in each cell with cytometer.
Cell line tumorigenicity G0/G1 S G2/M >G2/MsiCTR siCDT2 siCTR siCDT2 siCTR siCDT2 siCTR siCDT2
A549 YES 63    14 22 41 13 24    2 21
DLD1 YES 47    24 19 24 26 27    8 25
EBC1 YES 45    30 34 30 16 26    5 14
HCT116 YES 39    24 31 25 24 20    6 31
HeLa YES 40    21 21 14 25 24  14 41
HOS YES 42    28 16 16 37 39    5 17
HS764T YES 45    18 30 26 22 25    3 31
MG63 YES 61    30 13   9 23 43    3 18
SK-OV-3 YES 67    45 19 20 12 20    2 15
SUIT2 YES 59    23 25 39 13 28    3 10
TOV-21G YES 50    26 22 37 26 25    2 12
U2OS YES 43    10 20   9 33 21    4 60
HK2 NO 65    58 19 19 15 21    1  2
hTERT-HME-1 NO 72    73 15 15 11 10    2  2
HOB NO 75    72 14 13 10 13    1  2
HUVEC NO 63    57 14 16 20 24    3  3
MCF 10A NO 79    78  8   9 12 12    1  1
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Figure 2: CDT2 suppression induces rereplication and cell cycle blockade in cancer cells, but not in non-transformed 
cells. Analysis of the cell cycles of cancer (right panels) and non-transformed (left panels) cells after transfection with either the CDT2 
specific (siCDT2) or control (siCTR) small interfering RNA pool. Only in cancer cells CDT2 silencing resulted in alterations of the cell 
cycle. 
Figure 3: Loss of CDT2 affects the degradation of CDT1 in cancer, but not in non-transformed cells. (A-B), Western blot 
analysis of CDT1 and CDT2 proteins in cancer (A) and non-transformed (B) cell lines transfected with either CDT2 specific (siCDT2) or 
control (siCTR) small interfering RNA pool and treated with 10 µM CDDP for 6 hours. (C) Western blot analysis of p21 in p53 defective 
cancer cells (SK-OV-3) and in p53 proficient cancer (TOV-21G) and non-transformed (MCF 10A) cell lines, transfected as above. (D) 
Cytometric analysis of cell cycles of MG63 and U2OS cancer cell lines transfected with siRNA as above for 48 hours and then incubated 
in medium containing dimethylsulphoxide (DMSO) or 30nM AZD7762 CHK1 specific inhibitor for 24 hours. (E) Western blot analysis 
of CDT1 in A549 cancer cells, transfected with control and CDT2 specific siRNAs as in panels A and B and treated with CDDP (10 µM), 
staurosporin (1 µM), paclitaxel (10 nM) or TRAIL (100 µg/ml) for 6 hours. Significance was evaluated using the Student’s t-test: *P<0.05.
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(such as SK-OV-3) and in p53 proficient non-transformed 
cell lines (such as MCF-10A). 
The role of CDT2 in the degradation of CHK1 
in stressed cells has been already shown [13]. The 
inhibition of CHK1 kinase activity in CDT2 depleted cells 
resulted only in lack of G2/M arrest but did not change 
rereplication (Figure 3D).
To discriminate whether CDT2 was recruited and 
necessary in cancer cells because of the DNA damage 
or because of the apoptotic stimulus, CDT2-depleted 
cancer cells were treated with proapoptotic agents that do 
not induce DNA damage such as paclitaxel, TRAIL and 
staurosporin. Figure 3E shows that CDT2 depletion did 
not affect CDT1 degradation that occurred in response to 
the non-DNA-damaging agents.
In conclusion, these data demonstrate that CDT2 is 
indispensable for CDT1 degradation in response to DNA 
damage only in cancer cells.
DNA rereplication causes the death of CDT2 
depleted cells
To confirm the correlation between CDT2 depletion, 
rereplication and death we used the DNA replication 
inhibitor aphidicolin, which blocks cells at the G1/S 
transition [40]. In cancer cell lines, cell treatment with 
aphidicolin resulted in better cell survival after CDT2 
silencing (Figure 4A) and blocked rereplication (Figure 
4B). This shows that, after blocking the cell cycle, cancer 
cells were no longer able to undergo DNA replication and 
rereplication after CDT2 depletion. Reduced rereplication 
resulted in increased cell survival.
Cell death follows rereplication likely because 
rereplication causes DNA damage [41]. We measured 
the phosphorylated γH2AX histone in CDT2 depleted 
and control cells, as its phosphorylation is a reporter of 
double strand breaks (DBS) in DNA [42]. As a control, 
we compared cells treated with CDDP to untreated cells, 
Figure 4: DNA rereplication causes the death of CDT2 depleted cells. (A) Percentage of live cells (PI neg and Annexin V 
negative) after cell transfection with the CDT2 specific or control siRNAs, and after cell treatment with aphidicolin (APH, 0,25μg/ml) or 
control medium with DMSO (CTR) for 48 hours. Graphs show that cell treatment with aphidicolin reduced the proapoptotic effect of CDT2 
depletion. (B) Cycles of cells transfected as above and treated with aphidicolin (APH) or control medium with DMSO (CTR) as in panel 
A; cell cycle analysis shows that both U-2 OS and HeLa cells were blocked at the G1 phase by the treatment with aphidicolin and did not 
undergo rereplication. (C) Percentage of p-γH2AX positive cells in response to CDT2 depletion. Both cancer (U2-OS) and non-transformed 
(MCF 10A) cells, transfected with control and CDT2 specific siRNAs were labeled with an antibody directed against the phosphorylated 
form of γH2AX (Ser10). Labelled cells were measured using cytometry. Only in cancer cells CDT2 depletion resulted in an increase of 
p-γH2AX positive cells similar to that caused in both cancer and normal cells by CDDP. In panels A and C significance was evaluated using 
the Student’s t-test: ** P<0.01.
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as DNA damaging agents induce γH2AX phosphorylation. 
Both cancer and non-transformed cells treated with CDDP 
showed an increased phosphorylation in γH2AX (Figure 
4C). Figure 4C also shows that CDT2 depletion alone 
caused a similar effect in cancer cells, indicative of DNA 
damage, but not in non-transformed cells.
The transformed phenotype makes cancer cells 
addicted to CDT2
We have shown above that several cancer cell lines, 
with different mutation profiles, underwent rereplication 
after CDT2 suppression. We thus hypothesized that CDT2 
depletion is indispensable in cancer cells because of their 
basal stress phenotype associated to transformation, due 
to DNA damage, DNA replication stress and mitotic stress 
[43]. To understand whether the transformed phenotype 
makes cancer cells “addicted” to CDT2, we converted 
non-transformed cells into transformed and tumorigenic 
cells and silenced CDT2. Using Lentiviral vectors, 
we transduced the non-transformed, spontaneously 
immortalized MCF 10A and the h-TERT immortalized 
HME-1 breast epithelial cells to over-express the RAS 
oncogene activated by the p-Gly13Asp mutation (referred 
as KRAS G13D) (Supplementary Figure 3A and B). It was 
shown previously shown that both MCF 10A and h-TERT-
HME-1 expressing KRAS are transformed in vitro, 
i.e. able to grow in soft agar medium, and tumorigenic 
in vivo, i.e. able to form tumors when xenografted in 
immunocompromised mice [44, 45]. Moreover, the 
primary HOBs were transduced to overexpress the 
MET oncogene (Supplementary Figure 3C); these MET 
overexpressing HOB cells were previously shown to be 
transformed and tumorigenic [35].
As shown also above, the non–transformed cells 
were not affected by CDT2 suppression (Figure 5), while 
the expression of the hyperactivated oncogenes up-
regulated CDT2 expression (Supplementary Figure 3) and 
rendered cells susceptible to CDT2 loss (Figure 5A and 
5B). 
Conversely, the hTERT-HME-1 cells where the 
tumor suppressor genes RB1 or PTEN were knocked-
down by means of specific shRNA did not acquire a 
transformed and tumorigenic phenotype [45] and were 
insensitive to CDT2 loss (Figure 5B). Notably, the parental 
recipient hTERT-HME-1 cells carry already a functionally 
inactive TP53, because of the p.Cys176Phe mutation [45], 
that is one of the most frequent TP53 mutation and has 
been detected in multiple tumor types. 
Altogether these data show that the acquisition of a 
transformed phenotype makes cells susceptible to CDT2 
loss. 
DISCUSSION
This work shows that CDT2 is indispensable for the 
survival of cancer cells, but not of non-transformed cells. 
Cancer cell death due to CDT2 depletion was caused by 
rereplication. 
CDT2 is the substrate receptor of the CRL4CDT2 
ubiquitin ligase complex, which targets for destruction a 
number of substrates, among which the licensing factor 
Figure 5: Expression of an activated oncogene makes cells addicted to CDT2. The indicated cell populations were transfected 
with either the CDT2 specific (siCDT2) or a control (siCTR) small interfering RNA pool. Percentage of dead cells, measured with cytometry 
after cell labeling with propidium iodide, is shown in both panels. (A) The non-transformed MCF 10A breast cells and primary cultures 
of human osteoblasts (HOBs) were transduced to express the activated KRAS oncogene (KRAS-MCF 10A) and to over-express the MET 
oncogene (C42-HOB), respectively (see also Supplementary Figure 3). Both the KRAS-MCF 10A and the C42-HOB died after CDT2 
silencing, while the parental cells were unaffected. (B) The non-transformed hTERT-HME-1 breast cells were transduced either to express 
the activated KRAS oncogene or to express the PTEN or RB1 specific shRNA. Only the KRAS expressing hTERT-HME-1 were killed by 
CDT2 silencing. Significance was evaluated using the Student’s t-test: * P<0.05.
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CDT1 [2, 3, 5, 6], the CDK inhibitor p21 [7, 8], the 
checkpoint kinase CHK1 [13] and the p12 subunit of the 
DNA polymerase δ [20, 21]. CDT1 is a component of the 
prereplication complex that should be disassembled once 
the DNA synthesis begins. The activity of CDT1 during 
the cell cycle is tightly regulated by its association with 
the protein geminin and by its targeting for destruction by 
different ubiquitin ligase. Upon DNA damage, CDT1 is 
rapidly targeted for degradation by the CRL4CDT2 complex. 
This targeting safeguards genomic integrity and prevents 
rereplication while DNA repair is in progress. Indeed, it 
has been shown already that accumulated CDT1, because 
of reduced degradation results in DNA rereplication 
and cell apoptosis [39]. It has been also shown that 
CDT1 destruction occurs in cells after treatment with 
chemotherapeutics [46] and after UV irradiation [47, 
48]. We report here that in cancer cells, but not in non-
transformed cells, this mechanism was consistently 
impaired by CDT2 depletion. P21 is also a substrate of 
the CRL4CDT2 ubiquitin ligase. However, its involvement 
in the DNA rereplication and death of the twelve cancer 
cell lines studied here is unlikely as most of these lines 
are p53 defective and thus generally unable to respond to 
DNA damaging agents and apoptotic stimuli by increasing 
p21 expression. Indeed, we found that p21 degradation 
is impaired after CDT2 depletion only in p53 proficient 
cancer cell lines. In case of replication stress, lack of 
degradation of the checkpoint protein kinase CHK1 occurs 
in CDT2 depleted cancer cells [13]. We found that CDT2 
depleted cancer cells accumulated in G2/M. However, 
rereplication and cell death do not depend on CHK1 
reduced degradation, as cells in the presence of CHK1 
inhibitor did not accumulate in G2/M but underwent 
rereplication anyway. On the other side, it is not surprising 
that CDT2 depleted cells arrested in G2/M showed 
rereplicated DNA, because CDT1 degradation was no 
longer feasible and G2/M arrest enhances rereplication 
[49]. Moreover, CDT2 depleted likely accumulated the 
p12 subunit of the DNA polymerase δ, that allow fork 
progression after DNA damage [21]. 
It has been reported that the suppression of geminin, 
which is the specific protein inhibitor of CDT1, induces 
cell death in some, but not all, cancer cell lines, and also 
in some non-transformed cells, by inducing rereplication 
and activating the DNA damage checkpoint [50, 51]. We 
show here that CDT2 depletion resulted effective in killing 
cancer cells that are unaffected by geminin depletion [50]. 
One possible explanation is that CDT2 loss also results 
in lack of CHK1 degradation and cell accrual in G2/M, 
which as mentioned above enhances rereplication [49].
Rereplication was likely the cause of the death 
of CDT2-depleted cancer cells. Cell treatment with 
aphidicolin, which blocks cells at the G1/S transition [40] 
blocked rereplication and improved cell viability after 
CDT2 silencing. After CDT2 suppression cancer cells 
underwent an apoptotic type of death, as shown by the 
accumulation of active caspase-3. This is in agreement 
with the finding that rereplication generates single 
strand and double strand DNA breaks [52]. Indeed, we 
show that rereplication was associated to the increase 
of phosphorylated γH2AX histone that is the marker of 
double strand breaks in DNA. These data are in agreement 
with the finding of increased phosphorylation of γH2AX 
histone in two cancer cell lines where components of the 
CRL4CDT2 complex had been silenced [53]. It has been also 
shown that CDT2 depletion causes the phosphorylation, 
i.e. activation, of CHK1 [54] that follows generation of 
single strand DNA. Therefore, it is likely that damage-
responsive pathways sense rereplication as DNA damage 
[41] and eventually trigger the apoptotic machinery if the 
DNA damage repair pathways are not functioning, as in 
cancer cells. 
We show here that cell death, rereplication and 
CDT1 accumulation after CDT2 depletion occurred 
exclusively in cancer cells. This finding is important: 
if DNA rereplication and cell death could be induced 
selectively in cancer cells by CDT2 depletion, cancer 
cells could be killed without harming normal cells. 
The resistance of non-transformed cells to CDT2 
depletion was unexpected, as homozygous Cdt2−/− 
mouse embryos die at the two- to four-cell stage with 
an abnormal nuclear morphology [55]. This implies 
that in normal cells CRL4CDT2 is dispensable and one or 
more alternate mechanisms of CDT1 degradation were 
actively functioning while in cancer cells CRL4CDT2 is 
indispensable. It is worth noting that although several 
mechanisms regulate CDT1 degradation, all cancer cell 
lines shown here were similarly susceptible to CDT2 
loss, though they are characterized by different pattern of 
mutations. This wide effect of CDT2 depletion in suggests 
that CDT2 in not in a synthetic lethal relationship to 
another specific gene or pathway but becomes dominant 
in cancer cells. 
In agreement, the addition of a hyperactivated 
oncogene made transformed and tumorigenic the non-
transformed cells and was alone sufficient to make 
them dependent on CDT2. Thus, we propose that the 
spontaneously occurring and the ectopically obtained 
transformed cells are more vulnerable to the loss of CDT2, 
because they are in constant need of CRL4CDT2. This 
necessity might be associated to their stress phenotype, 
due to DNA damage, replication stress and mitotic stress 
[43]. Notably, the CRL4CDT2 complex is distinctively 
recruited for CDT1 degradation after DNA damage. 
The compound pattern of genetic alterations in cancer 
cells leads to a constitutive level of endogenous stimuli, 
which indeed results in activation of the response to DNA 
damage and replication stress [56]. Although altered, 
however, even cancer cells should save mechanisms that 
ensure the maintenance of cell replication. This is likely 
held by the same mechanisms that protect replication in 
normal cells. 
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In line, CDT2 expression is elevated in almost all 
the cancer cell lines studied here, as it is in several other 
cancer cell lines and human cancer samples [24, 25, 27-
29]. This can be correlated to the increased proliferation 
rate of cancer cells versus normal cells, as the non-
transformed highly proliferating tissues such as testis and 
bone marrow show an elevated level of CDT2 expression 
[23]. Moreover, it has been already demonstrated that 
replication stress, that could be constitutively increased 
in cancer cells, determines increased expression of CDT2 
in both mammalian cells [13] and fission yeast [22]. The 
exquisite sensitivity of cancer cells to CDT2 loss may 
explain, in part, why CDT2 overexpression is positively 
selected during tumorigenesis, as it might provide cancer 
cells with a selective advantage.
Interestingly, aspects of CRL4CDT2 loss are 
phenocopied by cell treatment with MLN4924 [57], a 
small molecule that inhibits the CRL-NEDD8-activating 
enzyme (NAE), which is also effective in actively 
proliferating non-transformed cells. This is expected 
as conjugation of the ubiquitin-like protein NEDD8 is 
required to activate all the CRL ligases. Thus, inhibiting 
the NAE by MLN4924 prevents destruction of numerous 
substrates of the CRLs, involved in cell proliferation and 
cancer pathways, such as not only CDT1 and p21, but also 
cyclins and checkpoint kinases [26, 39, 57, 58]. Therefore, 
treatment of cancer cells with MLN4924 triggers 
rereplication, DNA damage, G2 arrest, and apoptosis. 
MLN4924 is currently in clinical trials as an anticancer 
agent [59]. 
Altogether, data shown here suggest that cancer 
cells share some properties that make them “addicted” 
to CDT2. The term “oncogene addiction” [60] has 
been invented to pinpoint the dependence of cancer 
cells on a mutated cancer gene for tumor initiation and 
maintenance. One facet of oncogene addiction is synthetic 
lethality, as cancer cells might become addicted to a given 
oncogene when they lose a redundant gene or pathway 
that is in synthetic lethal interaction with the oncogenic 
pathway [61, 62]. Moreover, activation of an oncogene 
or loss of a tumor suppressor gene might install a flood 
of genetic, transcriptional and metabolic alterations 
[63-66] that make the cancer gene the only “dam to the 
flood” of pro-apoptotic signals [67]. Therefore, despite 
the focus on causative oncogenes as targets of cancer 
therapeutics, there is solid experimental evidence for non-
oncogenes that are rate-limiting to their pathways and 
represent potential drug targets. This phenomenon has 
been termed “non-oncogene addiction” in reference to 
the increased dependence of cancer cells on the normal 
cellular functions of certain genes, which themselves are 
not classical oncogenes [43]. Here we show that several 
cancer cell lines, which derive from diverse tissues and 
show different genetic alterations, all require CDT2 for 
proliferation and survival and are thus addicted to this 
non-oncogene. We can infer that CDT2 is in synthetic 
lethal interaction with different oncogenic pathway, the 
most likely Achille’s heel being the stress phenotype of 
cancer cells, due to the DNA damage represented by the 
widespread genetic aberration and the replication and 
mitotic stress caused by uncontrolled proliferation. 
METHODS
Cell lines, chemicals and antibodies. 
Twelve cancer cell lines (Table S1) from different 
human tumors and the non-transformed human cell 
lines HK2, hTERT-HME1, MCF 10A and MRC-5 cell 
lines were purchased from the American Type Culture 
Collection (Manassas, VA) and grown as suggested by 
the provider. Primary cultures of human cells HUVEC 
and osteoblasts (HOB) were obtained as previously 
described [34, 35]. MCF 10A and hTERT-HME-1 cells 
were engineered to overexpress the KRAS G13D cDNA 
by infection with a Lentiviral vector harboring the mutated 
KRAS allele downstream a constitutive promoter as 
previously reported [45]. C42 MET over-expressing HOB 
clone were obtained as previously reported [35]. Details of 
other reagents are described in Supplementary Materials 
and Methods. 
RNA Interference
RNAi experiments were performed using ON-
TARGET plus SMART pool, a mixture of four siRNAs 
targeting one gene (Dharmacon, Lafayette,CO). In each 
experiment ON-TARGET plus Non-Targeting Pool 
(Dharmacon, Lafayette, CO) was used as negative control. 
The sequences of the oligonucleotides are reported in 
Supplementary Materials and Methods. Cell lines were 
plated at 30-40% confluence and transfected with the 
indicated siRNA pools (200nM) using Oligofectamine 
(Invitrogen, Eugene, OR) according to the manufacturer’s 
instructions. The mRNA downmodulation of target genes 
was assayed with quantitative RT-PCR and with Western 
Blot analysis 48h and 72h after transfection, respectively. 
Experiments were performed 72 hours after transfection, 
if not otherwise indicated. 
RNA extraction and Quantitative Reverse 
Transcription-PCR 
RNA extraction and qPCR was carried out as 
described previously [33]. Details are reported in 
Supplementary Materials and Methods.
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Protein extraction and Western Blot analysis 
Total protein extraction was performed by directly 
incubating cells in SDS containing lysis buffer at 95°C 
for 5 minutes. Proteins were separated by PAGE and 
transferred to nitrocellulose sheets. Equal amounts of 
proteins (100 µg) were loaded in each lane. Blots were 
probed and when necessary re-probed with the different 
antibodies as indicated in the Result section. Bound 
antibodies were detected using the appropriate peroxidase-
conjugated secondary antibody and revealed by Enhanced 
Chemiluminescence (Amersham, United Kingdom).
Flow cytometry analysis
Cell cycle analysis was based on DNA content. 
Details are reported in Supplementary Materials and 
Methods.
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